Market Cap | 83.59M | P/E | - | EPS this Y | -21.90% | Ern Qtrly Grth | - |
Income | - | Forward P/E | -2.91 | EPS next Y | 15.30% | 50D Avg Chg | 2.00% |
Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | 94.00% |
Dividend | N/A | Price/Book | 2.94 | EPS next 5Y | - | 52W High Chg | - |
Recommedations | 3.00 | Quick Ratio | - | Shares Outstanding | 2.76M | 52W Low Chg | 555.00% |
Insider Own | 3.69% | ROA | - | Shares Float | - | Beta | - |
Inst Own | 7.87% | ROE | - | Shares Shorted/Prior | 28.97K/11.76K | Price | 30.03 |
Gross Margin | - | Profit Margin | - | Avg. Volume | 27,555 | Target Price | 24.00 |
Oper. Margin | - | Earnings Date | Aug 9 | Volume | 1 | Change | 0.00% |
Neovasc Inc., a specialty medical device company, develops, manufactures, and markets products for cardiovascular marketplace in Europe and internationally. Its products include Tiara for the transcatheter treatment of mitral valve disease; and the Neovasc Reducer for the treatment of refractory angina. The company was formerly known as Medical Ventures Corp. and changed its name to Neovasc Inc. in July 2008. Neovasc Inc. was incorporated in 2000 and is headquartered in Richmond, Canada. As of April 11, 2023, Neovasc Inc. operates as a subsidiary of Shockwave Medical, Inc.
SVB Leerink | Outperform | Nov 6, 20 |
H.C. Wainwright | Buy | Nov 25, 20 |
Canaccord Genuity | Buy | Nov 25, 20 |
H.C. Wainwright | Buy | Nov 25, 20 |
Leerink Swann | Outperform | Nov 25, 20 |
Canaccord Genuity | Buy | Nov 25, 20 |
Leerink Swann | Outperform | Nov 25, 20 |
Ladenburg Thalmann | Neutral | Nov 25, 20 |
Ladenburg Thalmann | Buy | Nov 25, 20 |